摘要
目的 研究重组人可溶性血管内皮细胞生长抑制因子 (VEGI)体外抗血管内皮细胞增殖的活性。 方法 MTT法检测重组人可溶性 VEGI对血管内皮细胞及肿瘤细胞增殖的抑制活性。 结果 在体外 ,重组人可溶性 VEGI可强烈抑制人脐静脉内皮细胞 ECV30 4、大鼠肺源毛细血管内皮细胞 (MPCEC)及新生牛主动脉内皮细胞(BAEC)的增殖 ,不能抑制黑色素瘤细胞 B- 16和小鼠成纤维细胞 L - 92 9的增殖。 结论 重组人可溶性 VEGI能作用于不同来源的血管内皮细胞 ,而对肿瘤细胞增殖无抑制作用 。
Objective\ To test the recombinant soluble vascular endothelial growth inhibitor(\{VEGI\}) for its inhibition activity against the proliferation of new\|born bovine aortic endothelial cells(BAEC), human umbilical vein endothelial cell line ECV304 and mouse pulmonary capillary endothelial cells(MPCEC), B\|16 melanoma cells and L\|929 fibroblast in vitro.\ Methods\ The effects of recombinant VEGI on the proliferation of vascular endothelial cells and tumor cells were assayed by MTT technique in vitro.\ Results\ The recombinant VEGI inhibited the proliferation of BAEC, ECV304 and MPCEC in vitro in a dose\|dependent manner.\ In contrast, recombinant VEGI had no influence on the growth of B\|16 and L\|929 cells under the same culture conditions.\ Conclusion\ The recombinant soluble VEGI could specifically inhibit the proliferation of endothelial cells but could not inhibit the proliferation of tumor cells in vitro.\ This data suggest that VEGI might be highly valuable to angiogenesis inhibition based cancer therapy.
出处
《福建医科大学学报》
2001年第4期318-321,共4页
Journal of Fujian Medical University
关键词
内皮生长因子
抑制因子
新生血管化
血管内皮细胞增殖
肿瘤
endothelial growth factor
inhibitor,immunity
endothelial,vessel
neoformative vascularzation,pathological
